Alcon Inc (ALC) (Full Year 2025) Earnings Call Highlights: Strong Revenue Growth Amid Market …

GuruFocus News

Thu, February 26, 2026 at 4:01 AM GMT+9 4 min read

In this article:

ALC

+2.45%

This article first appeared on GuruFocus.

**Revenue:** $2.7 billion, up 7% year-over-year.

**Surgical Franchise Revenue:** $1.5 billion, up 6% year-over-year.

**Implantable Sales:** $474 million, up 2% year-over-year.

**Consumables Sales:** $794 million, up 5% year-over-year.

**Equipment Sales:** $277 million, up 18% year-over-year.

**Vision Care Revenue:** $1.2 billion, up 7% year-over-year.

**Contact Lens Sales:** $683 million, up 4% year-over-year.

**Ocular Health Sales:** $474 million, up 12% year-over-year.

**Core Gross Margin:** 62.5%, down 50 basis points year-over-year.

**Core Operating Margin:** 19%, down 160 basis points year-over-year.

**Core Diluted Earnings Per Share:** $0.78.

**Free Cash Flow:** $1.7 billion in 2025, up from $1.6 billion in 2024.

**Shareholder Returns:** $848 million returned in 2025, including $682 million in share repurchases and $166 million in dividends.

**Tariff-Related Charges:** $91 million in 2025.

**2026 Sales Growth Outlook:** 5% to 7%.

**2026 Core Diluted EPS Growth Outlook:** 9% to 12%.

Warning! GuruFocus has detected 5 Warning Sign with FPLSF.

Is ALC fairly valued? Test your thesis with our free DCF calculator.

Release Date: February 25, 2026

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Alcon Inc (NYSE:ALC) reported a 7% increase in fourth-quarter sales, reaching $2.7 billion, driven by strong performance in both surgical and vision care segments.

The Unity VCS and CS platforms have been well-received, with Unity VCS recognized for outstanding technology achievements, contributing significantly to equipment sales growth.

Panoptics Pro has stabilized trifocal share in the US and exceeded expectations, with plans to expand into Japan and Australia.

The launch of Triptier in the dry eye category is tracking ahead of expectations, with strong early refill rates and broad prescriber enthusiasm.

Alcon Inc (NYSE:ALC) generated $1.7 billion in free cash flow in 2025, enabling significant shareholder returns through share repurchases and dividend payments.

Negative Points

The global procedural volumes for cataract surgeries grew only 3%, indicating a softer market environment.

Alcon Inc (NYSE:ALC) faced increased competition in the IOL market, particularly internationally, affecting market share.

Fourth-quarter core gross margin decreased by 50 basis points year over year, primarily due to incremental tariffs.

Operating margin was down 160 basis points, impacted by lower gross margin and increased sales and marketing investments.

The company incurred $91 million in tariff-related charges in 2025, affecting overall financial performance.

 






Story Continues  

Q & A Highlights

Q: Could you give us a sense of how comfortable you are today in terms of visibility regarding your guidance, especially considering the strong exit rate in the fourth quarter? A: The markets improved in the fourth quarter, but they aren’t quite back to normal yet. We estimate the surgical market finished at about 3% and vision care at 4%, which is where we expect them to be next year. We believe our guidance reflects a balanced view of market conditions.

Q: How much did Unity contribute to equipment growth in Q4, and how should we think about equipment growth in 2026? A: Unity for retina, our VCS, saw revenue double year-on-year, contributing significantly to equipment growth. We have good visibility into a funnel of contracts ready to go, and we feel confident about maintaining the growth trajectory.

Q: Can you describe the visibility you have on the Unity order book and your confidence in sustaining a healthy double-digit growth rate in equipment as we enter 2026? A: We have a detailed view of our funnel, tracking everything from prospects to installations. We are confident in the demand and expect the product to perform well this year.

Q: What are your expectations for the launch of Panoptics Pro outside the US, and when do you expect growth in this segment to align with the market? A: We are launching Panoptics Pro in Japan and Australia and awaiting regulatory approval in Europe. We expect True Plus and Vividy 20 to launch later this year. These launches should help us compete effectively and align growth with the market.

Q: How are you seeing the dynamics in the US IOL cataract market, particularly regarding surgeon capacity? A: Surgeon productivity is a key dynamic. Practices are increasing surgery days by employing optometrists for pre-op and post-op work and using paraprofessionals. There is also a lot of ASC movement, which should help normalize capacity.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Terms and Privacy Policy

Privacy Dashboard

More Info